BRPI0816994A2 - Derivado uracila ou timina para tratar hepatite c - Google Patents

Derivado uracila ou timina para tratar hepatite c

Info

Publication number: BRPI0816994A2
Authority: BR; Brazil
Prior art keywords: thymin; uracyl; derivative; treat hepatitis; hepatitis
Prior art date: 2007-09-17

Application number

Other languages

English (en)

Inventor

Wagner Rolf

Michael D Tufano

Kent D Stewart

Todd W Rockway

John T Randolph

John K Pratt

Christopher E Motter

Clarence J Maring

Kenton L Longenecker

Yaya Liu

Dachun Liu

Allan C Krueger

Warren M Kati

Douglas K Hutchinson

Peggy P Huang

Charles A Flentge

Pamela L Donner

David A Degoey

David A Betebenner

David M Barnes

Shuang Chen

Thaddeus S Franczyk

Yi Gao

Anthony R Haight

John E Hengeveld

Rodger F Henry

Brian J Kotecki

Xiaochun Lou

Kathy Sarris

Geoff G Z Zhang

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-17

Filing date

2008-09-17

Publication date

2015-03-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0816994(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-17 Application filed by Abbott Lab filed Critical Abbott Lab

2015-03-24 Publication of BRPI0816994A2 publication Critical patent/BRPI0816994A2/pt

2019-12-24 Publication of BRPI0816994B1 publication Critical patent/BRPI0816994B1/pt

2021-05-25 Publication of BRPI0816994B8 publication Critical patent/BRPI0816994B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Peptides Or Proteins (AREA)

BRPI0816994A 2007-09-17 2008-09-17 derivado uracila ou timina para tratar hepatite c BRPI0816994B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97287707P	2007-09-17	2007-09-17
US9679108P	2008-09-13	2008-09-13
PCT/US2008/076576 WO2009039127A1 (en)	2007-09-17	2008-09-17	Uracil or thymine derivative for treating hepatitis c

Publications (3)

Publication Number	Publication Date
BRPI0816994A2 true BRPI0816994A2 (pt)	2015-03-24
BRPI0816994B1 BRPI0816994B1 (pt)	2019-12-24
BRPI0816994B8 BRPI0816994B8 (pt)	2021-05-25

Family

ID=39948002

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816994A BRPI0816994B8 (pt)	2007-09-17	2008-09-17	derivado uracila ou timina para tratar hepatite c

Country Status (30)

Country	Link
US (3)	US8415351B2 (pt)
EP (2)	EP2725015A1 (pt)
JP (2)	JP5734654B2 (pt)
KR (2)	KR101660360B1 (pt)
CN (2)	CN102746239B (pt)
AR (2)	AR070027A1 (pt)
AU (1)	AU2008302448B2 (pt)
BR (1)	BRPI0816994B8 (pt)
CA (2)	CA2976793A1 (pt)
CL (2)	CL2008002794A1 (pt)
CO (1)	CO6260076A2 (pt)
CR (2)	CR11316A (pt)
DO (2)	DOP2010000084A (pt)
ES (1)	ES2453591T3 (pt)
GT (1)	GT201000061A (pt)
IL (1)	IL204547A (pt)
IN (1)	IN2012DN05113A (pt)
MX (2)	MX2010002905A (pt)
MY (1)	MY162760A (pt)
NZ (3)	NZ600371A (pt)
PA (1)	PA8796201A1 (pt)
PE (2)	PE20090705A1 (pt)
PH (1)	PH12013500365A1 (pt)
RU (2)	RU2543620C2 (pt)
SG (1)	SG183733A1 (pt)
TW (2)	TWI534137B (pt)
UA (1)	UA117800C2 (pt)
UY (1)	UY31344A1 (pt)
WO (1)	WO2009039127A1 (pt)
ZA (2)	ZA201204223B (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2523864T3 (es)	2007-09-17	2014-12-02	Abbvie Bahamas Ltd.	Pirimidinas antiinfecciosas y usos de las mismas
RU2542099C2 (ru)	2007-09-17	2015-02-20	Эббви Бахамаз Лтд.	N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
EP2725015A1 (en)	2007-09-17	2014-04-30	AbbVie Bahamas Ltd.	Uracil or thymine derivative for treating hepatitis c
MX2010005356A (es) *	2007-11-16	2010-05-27	Schering Corp	Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
AU2009273327A1 (en)	2008-07-23	2010-01-28	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds
EP2334662A1 (en)	2008-09-26	2011-06-22	F. Hoffmann-La Roche AG	Pyrine or pyrazine derivatives for treating hcv
ES2488821T3 (es) *	2009-03-24	2014-08-29	Abbvie Bahamas Ltd.	Proceso de preparación de un compuesto antiviral
JP5571167B2 (ja) *	2009-03-25	2014-08-13	アッヴィ・インコーポレイテッド	抗ウイルス組成物およびこの使用
WO2010111653A2 (en) *	2009-03-27	2010-09-30	The Uab Research Foundation	Modulating ires-mediated translation
KR20120011880A (ko)	2009-04-25	2012-02-08	에프. 호프만-라 로슈 아게	헤테로사이클릭 항바이러스성 화합물
TWI428332B (zh)	2009-06-09	2014-03-01	Hoffmann La Roche	雜環抗病毒化合物
WO2010149598A2 (en) *	2009-06-24	2010-12-29	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compound
JP2011057661A (ja) *	2009-08-14	2011-03-24	Bayer Cropscience Ag	殺虫性カルボキサミド類
WO2011033045A1 (en)	2009-09-21	2011-03-24	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds
JP2013511489A (ja) *	2009-11-21	2013-04-04	エフ．ホフマン−ラロシュアーゲー	複素環式抗ウイルス化合物
KR20120104343A (ko) *	2009-12-14	2012-09-20	에프. 호프만-라 로슈 아게	헤테로환형 항바이러스성 화합물
US9216952B2 (en) *	2010-03-23	2015-12-22	Abbvie Inc.	Process for preparing antiviral compound
JP5651239B2 (ja)	2010-07-07	2015-01-07	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	複素環式抗ウイルス化合物
US8975443B2 (en)	2010-07-16	2015-03-10	Abbvie Inc.	Phosphine ligands for catalytic reactions
AU2015201698B2 (en) *	2010-07-16	2017-02-02	Abbvie Ireland Unlimited Company	Process for preparing antiviral compounds
US9255074B2 (en)	2010-07-16	2016-02-09	Abbvie Inc.	Process for preparing antiviral compounds
EP2593226B1 (en)	2010-07-16	2018-11-14	AbbVie Ireland Unlimited Company	Phosphine ligands for catalytic reactions
EP2593439B1 (en) *	2010-07-16	2016-08-17	AbbVie Bahamas Ltd.	Process for preparing antiviral compounds
RU2436786C1 (ru) *	2010-07-23	2011-12-20	Александр Васильевич Иващенко	Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) *	2010-08-10	2012-02-16	塩野義製薬株式会社	Ｎｐｙｙ５受容体拮抗作用を有するヘテロ環誘導体
CN103068819B (zh)	2010-08-13	2014-08-13	弗·哈夫曼-拉罗切有限公司	杂环抗病毒化合物
CN102675092B (zh) *	2011-03-14	2014-11-05	江苏中丹药物研究有限公司	一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US9248193B2 (en)	2011-03-18	2016-02-02	Abbvie Inc.	Formulations of phenyl uracil compounds
SG10202010626PA (en) *	2011-03-31	2020-11-27	Schaefer Konstanze	Perfluorinated compounds for the non-viral transfer of nucleic acids
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
JP5734124B2 (ja) *	2011-07-21	2015-06-10	株式会社東邦アーステック	１，３−ジヨードヒダントイン類の製造方法
EP2740728A4 (en)	2011-08-01	2015-04-01	Sumitomo Dainippon Pharma Co Ltd	URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
AU2015200715A1 (en) *	2011-10-21	2015-03-05	Abbvie Ireland Unlimited Company	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
SG2014011647A (en)	2011-10-21	2014-08-28	Abbvie Inc	Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
SG2014011670A (en)	2011-10-21	2014-10-30	Abbvie Inc	Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
JP6078640B2 (ja)	2012-05-15	2017-02-08	ノバルティスアーゲー	Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
AP3613A (en)	2012-05-15	2016-02-29	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
WO2013171641A1 (en)	2012-05-15	2013-11-21	Novartis Ag	Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
ES2665539T3 (es)	2012-05-15	2018-04-26	Novartis Ag	Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
EP2866807A2 (en)	2012-06-27	2015-05-06	Abbvie Inc.	Methods for treating hcv
JP6469571B2 (ja) *	2012-08-21	2019-02-13	アッヴィ・アイルランド・アンリミテッド・カンパニー	抗ウイルス性化合物を調製するための方法
EP2908808A1 (en)	2012-10-18	2015-08-26	Abbvie Inc.	Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) *	2012-11-20	2014-06-05	Toyobo Co Ltd	ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
MX2015017953A (es)	2013-07-02	2016-10-28	Abbvie Inc	Metodos para tratar el virus de hepatitis c.
AR096816A1 (es)	2013-07-08	2016-02-03	Bayer Cropscience Ag	Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con c-n como agentes para combatir parásitos
SI3043803T1 (sl)	2013-09-11	2022-09-30	Emory University	Nukleotidne in nukleozidne sestave in njihova uporaba
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
US20150209403A1 (en)	2014-01-28	2015-07-30	Abbvie Inc.	Dose Adjustment
JP6466461B2 (ja)	2014-02-03	2019-02-06	ヴァイティーファーマシューティカルズ，インコーポレイテッド	Ｒｏｒガンマのジヒドロピロロピリジン阻害剤
WO2015197028A1 (en) *	2014-06-28	2015-12-30	Sunshine Lake Pharma Co., Ltd.	Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016004513A1 (en) *	2014-07-11	2016-01-14	Simon Fraser University	Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MY187540A (en)	2014-08-01	2021-09-28	Nuevolution As	Compounds active towards bromodomains
WO2016040588A1 (en)	2014-09-11	2016-03-17	Abbvie Inc.	Treatment of hcv by administering four different anti-hcv compounds with food
AU2015333610B2 (en)	2014-10-14	2019-11-07	Vitae Pharmaceuticals, Llc	Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en)	2014-11-05	2017-12-19	Vitae Pharmaceuticals, Inc.	Isoindoline inhibitors of ROR-gamma
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016105547A1 (en)	2014-12-24	2016-06-30	Concert Pharmaceuticals, Inc.	Deuterated dasabuvir
RU2590952C1 (ru) *	2015-05-26	2016-07-10	Вячеслав Энгельсович Семёнов	Средство гепатопротекторного действия
WO2016196280A1 (en)	2015-06-02	2016-12-08	E I Du Pont De Nemours And Company	Heterocycle-substituted bicyclic pesticides
JP2018525371A (ja) *	2015-07-30	2018-09-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	アリール置換された二環式ヘテロアリール化合物
ES2856931T3 (es)	2015-08-05	2021-09-28	Vitae Pharmaceuticals Llc	Moduladores de ROR-gamma
BR112018010018A2 (pt)	2015-11-20	2018-11-21	Vitae Pharmaceuticals Inc	moduladores de ror-gama
TWI757266B (zh)	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
US9481674B1 (en)	2016-06-10	2016-11-01	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
MX2020000887A (es)	2017-07-24	2020-07-22	Vitae Pharmaceuticals Llc	Inhibidores de ror?.
CN107266373A (zh) *	2017-08-01	2017-10-20	安徽拜善晟制药有限公司	一种原料药达沙布韦的制备方法
WO2019186343A1 (en)	2018-03-26	2019-10-03	Novartis Ag	N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
CN110483496B (zh) *	2019-07-17	2021-05-04	杭州市西溪医院	一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN114521196A (zh) *	2019-09-16	2022-05-20	诺华股份有限公司	双官能团降解剂及其使用方法
EP3819006A1 (en)	2019-11-05	2021-05-12	Technische Universität Dresden	Compounds with thymine skeleton for use in medicine
CN111518036A (zh) *	2020-04-29	2020-08-11	杭州勇诚睿生物科技有限公司	一种达沙布韦关键中间体的制备方法
US12274700B1 (en)	2020-10-30	2025-04-15	Accencio LLC	Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4239888A (en) *	1974-11-04	1980-12-16	Pfizer Inc.	1-Phenyluracils
JPS60243017A (ja) *	1984-05-16	1985-12-03	Kyowa Hakko Kogyo Co Ltd	抗けいれん組成物
US5084084A (en) *	1989-07-14	1992-01-28	Nissan Chemical Industries Ltd.	Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) *	1989-07-14	1992-09-03	Nissan Chemical Industries Ltd.	Uracil derivatives and herbicides containing the same as active ingredient
CA2036304C (en)	1990-02-15	2001-04-17	Takehiko Naka	Pyrimidinedione derivatives, their production and use
NL9001075A (pt) *	1990-05-04	1991-12-02	Duphar Int Res
EP0489480A1 (en) *	1990-12-05	1992-06-10	Nissan Chemical Industries Ltd.	Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja)	1992-02-07	1993-08-24	Nikko Kyodo Co Ltd	肝臓障害治療薬
DE19528305A1 (de)	1995-08-02	1997-02-06	Bayer Ag	Substituierte Phenyluracile
HU229105B1 (en)	1999-12-06	2013-07-29	Hoffmann La Roche	4-pyrimidinyl-n-acyl-l-phenylalanines
US6380387B1 (en) *	1999-12-06	2002-04-30	Hoffmann-La Roche Inc.	4-Pyrimidinyl-n-acyl-l phenylalanines
RU2264395C2 (ru) *	2000-02-04	2005-11-20	Сумитомо Кемикал Компани, Лимитед	Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
IL141034A0 (en) *	2000-02-04	2002-02-10	Sumitomo Chemical Co	Uracil compounds and use thereof
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) *	2003-06-13	2006-06-19	주식회사 엘지생명과학	Ｃ형 간염 바이러스의 억제제
US7163937B2 (en)	2003-08-21	2007-01-16	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
JO2934B1 (en) *	2006-06-23	2015-09-15	سميث كلاين بيتشام كوربوريشن	Prolyl hydroxylase inhibitors
EP2725015A1 (en) *	2007-09-17	2014-04-30	AbbVie Bahamas Ltd.	Uracil or thymine derivative for treating hepatitis c
RU2542099C2 (ru) *	2007-09-17	2015-02-20	Эббви Бахамаз Лтд.	N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
ES2523864T3 (es) *	2007-09-17	2014-12-02	Abbvie Bahamas Ltd.	Pirimidinas antiinfecciosas y usos de las mismas
AU2009273327A1 (en)	2008-07-23	2010-01-28	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds

2008
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown

Also Published As

Publication number	Publication date
IN2012DN05113A (pt)	2015-10-23
US20140235638A1 (en)	2014-08-21
IL204547A0 (en)	2010-11-30
US20120213733A1 (en)	2012-08-23
AR087472A2 (es)	2014-03-26
PE20090705A1 (es)	2009-07-17
DOP2010000084A (es)	2010-06-15
MY162760A (en)	2017-07-14
AU2008302448A1 (en)	2009-03-26
PE20130209A1 (es)	2013-03-24
CN101801935B (zh)	2014-12-03
JP2013049681A (ja)	2013-03-14
PA8796201A1 (es)	2009-04-23
ZA201204224B (en)	2015-12-23
IL204547A (en)	2016-04-21
BRPI0816994B8 (pt)	2021-05-25
NZ600371A (en)	2014-07-25
US20110070193A1 (en)	2011-03-24
EP2222646A1 (en)	2010-09-01
CL2008002794A1 (es)	2009-09-04
CR20150238A (es)	2015-07-01
CR11316A (es)	2010-10-05
EP2725015A1 (en)	2014-04-30
KR20150117632A (ko)	2015-10-20
AR070027A1 (es)	2010-03-10
RU2013104270A (ru)	2014-08-10
CN102746239A (zh)	2012-10-24
ZA201204223B (en)	2015-12-23
CN102746239B (zh)	2016-02-10
US8415351B2 (en)	2013-04-09
TW201443027A (zh)	2014-11-16
RU2599635C2 (ru)	2016-10-10
CL2013000372A1 (es)	2013-10-04
US8685991B2 (en)	2014-04-01
US9095590B2 (en)	2015-08-04
ES2453591T3 (es)	2014-04-08
NZ584720A (en)	2012-07-27
TWI437994B (zh)	2014-05-21
UA117800C2 (uk)	2018-10-10
MX338555B (es)	2016-04-20
NZ618277A (en)	2015-07-31
CO6260076A2 (es)	2011-03-22
RU2543620C2 (ru)	2015-03-10
CA2699981C (en)	2017-08-22
CA2699981A1 (en)	2009-03-26
DOP2010000396A (es)	2013-12-31
KR101660360B1 (ko)	2016-09-27
WO2009039127A1 (en)	2009-03-26
BRPI0816994B1 (pt)	2019-12-24
SG183733A1 (en)	2012-09-27
JP2010539186A (ja)	2010-12-16
HK1147256A1 (en)	2011-08-05
RU2010114828A (ru)	2011-10-27
MX2010002905A (es)	2010-07-05
TW200918066A (en)	2009-05-01
PH12013500365A1 (en)	2014-09-08
TWI534137B (zh)	2016-05-21
KR20100068289A (ko)	2010-06-22
EP2222646B1 (en)	2014-01-22
UY31344A1 (es)	2009-04-30
KR101552474B1 (ko)	2015-09-11
CA2976793A1 (en)	2009-03-26
CN101801935A (zh)	2010-08-11
AU2008302448B2 (en)	2014-11-06
GT201000061A (es)	2012-03-26
JP5734654B2 (ja)	2015-06-17

Publication	Publication Date	Title
BRPI0816994A2 (pt)	2015-03-24	Derivado uracila ou timina para tratar hepatite c
BRPI0913931A2 (pt)	2015-10-20	poliolefinas modificadas
BRPI0916233A2 (pt)	2018-03-13	compostos heterocíclicos antivirais
PT2231689T (pt)	2016-10-07	Novos nucleósidos 7-deazapurina citostáticos
BRPI0923497A2 (pt)	2019-09-24	derivados de piridazinona
BRPI0811509A2 (pt)	2014-11-18	Mouse
BRPI0911161A2 (pt)	2015-10-06	derivado de piridazinona
BRPI0914614A2 (pt)	2019-09-24	2-arilaminoquinazolinas para tratar doenças proliferativas
BRPI0910534A2 (pt)	2015-09-29	terapia antiviral
DE602008003849D1 (de)	2011-01-20	Lenkungsdämpfer
BRPI0920513A2 (pt)	2019-09-24	derivados de pirina ou pirazina para tratar hcv
BRPI0924121A2 (pt)	2019-09-24	compostos antivirais heterocíclicos
BRPI0914936A2 (pt)	2015-10-20	naftiridininonas como inibidores de aurora quinase
BRPI0906881A2 (pt)	2015-07-07	Articulação de direção
BRPI0819633A2 (pt)	2015-05-05	Métodos para produzir poliolefinas
EP2313202A4 (en)	2014-12-31	DIRECT DEPOSIT CYCLONE
BRPI0917210A2 (pt)	2015-11-10	exoterma controlada de formulações de cianocrilato
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
BRPI0822264A2 (pt)	2014-09-30	Dapsona para tratar rosácea
PL2162238T3 (pl)	2014-07-31	Obróbka powierzchni termicznie modyfikowanego drewna
BR112012010510A2 (pt)	2016-11-29	trator
BRPI0910931A2 (pt)	2019-09-24	ciclopentanos substituídos terapêuticos
DK2173197T3 (da)	2019-09-23	Fremgangsmåde
EP2308001A4 (en)	2011-09-07	TRANSLATION OF DRM SYSTEM REQUIREMENTS
HRP20170026T1 (hr)	2017-04-07	Poboljšani sustav za spaljivanje

Legal Events

Date	Code	Title	Description
2015-09-15	B25A	Requested transfer of rights approved	Owner name: ABBVIE INC. (US)
2015-10-06	B25A	Requested transfer of rights approved	Owner name: ABBVIE BAHAMAS LTD. (US)
2017-05-23	B25A	Requested transfer of rights approved	Owner name: ABBVIE IRELAND UNLIMITED COMPANY (BM)
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-23	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-12-03	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-12-24	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2019, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF